斑秃 (AA) 是一种由细胞因子失调引起的自身免疫性疾病，导致脱发，最近的数据表明炎症可能会全身发生。炎症细胞因子的全身增加可能会增加血栓事件的发生率，包括深静脉血栓、中风、心肌梗塞和肺栓塞。随着 JAK 抑制剂治疗 AA 的使用变得越来越普遍，进一步研究这种潜在关系以防止此类事件恶化非常重要。这项病例对照研究的目的是利用 All of Us 数据库确定血栓事件与斑秃之间的关联是否增加。我们将 926 名 AA 患者与没有任何脱发的对照进行 4:1 匹配，我们发现 AA 患者的静脉血栓栓塞 (VTE) 发生率显着增加 (p = 0.009)。然后使用多变量条件逻辑回归来估计 AA 与 VTE 相关的几率，并控制常见的高凝因素（心房颤动、雌激素替代、肥胖、恶性肿瘤、怀孕和吸烟史）。我们发现，在控制这些危险因素后，有和没有 AA 患者的 VTE 发生率没有显着差异（OR：1.549，CR 95%（0.862，2.783））。虽然最近的报告表明斑秃与静脉血栓栓塞显着相关，但在控制高凝因素后，我们没有观察到显着的关联。© 2024。作者获得 Springer-Verlag GmbH 德国（Springer 旗下公司）的独家许可自然。

Alopecia areata (AA) is an autoimmune disease driven by cytokine dysregulation resulting in hair loss, and recent data suggests inflammation may be occurring systemically. This systemic increase in inflammatory cytokines may increase the incidence of thrombotic events, including deep vein thrombosis, stroke, myocardial infarction, and pulmonary embolism. As the use of JAK inhibitors for AA becomes more common, it is important to further investigate this potential relationship to prevent exacerbation of such events. The purpose of this case-control study was to determine if there is an increased association between thrombotic events and alopecia areata using the All of Us database. We matched 926 patients with AA 4:1 to controls without any alopecia, and we found that there was a statistically significant increase in the incidence of venous thromboembolism (VTE) in patients with AA (p = 0.009). Multivariable conditional logistic regression was then used to estimate the odds of AA in relation to VTE, controlling for common hypercoagulable factors (atrial fibrillation, estrogen replacement, obesity, malignancy, pregnancy, and smoking history). We found that after controlling for these risk factors, there was no significant difference in the incidence in VTE between those with and without AA (OR: 1.549, CR 95% (0.862, 2.783)). While recent reports have suggested alopecia areata to be significantly associated with venous thromboembolisms, we did not observe a significant association after controlling for hypercoagulable factors.© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.